Research and analysis
Chemotherapy for breast and lung cancer: 30-day mortality
A companion report to the Lancet Oncology paper, providing trust-level analyses.
Trust-level 30-day mortality after systemic anticancer treatment for breast and lung cancer in England
Ref: PHE gateway ref 2016250 PDF, 1.32MB, 67 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email firstname.lastname@example.org. Please tell us what format you need. It will help us if you say what assistive technology you use.
This cancer report is co-authored by PHE’s National Cancer Registration and Analysis Service and Cancer Research UK and is the first major report using world-first systemic anticancer treatment (SACT) data.
NHS hospital trusts began submitting data in April 2012, and submission became mandatory for all NHS hospital trusts in England from April 2014.
The data gives new, trust-level insights about the real-world chemotherapy treatment of patients in the NHS in England which was previously only available from clinical trials.
Published: 31 August 2016
From: Public Health England